Delcath Systems to Present at Upcoming Virtual Investor Conferences
05 August 2021 - 11:00PM
Delcath Systems, Inc. (Nasdaq:
DCTH), an
interventional oncology company focused on the treatment of rare
primary and metastatic cancers of the liver, announced today it
will participate in two upcoming conferences:
BTIG Virtual Biotechnology Conference
- Date and Time:
August 9, 2021: 10:00-10:25 AM ET
- Webcast: BTIG
hosted events are intended for prospective and existing BTIG
clients only. To listen to the live event, please contact your BTIG
representative with interest.
- Management will
also host 1x1 investor meetings during the conference.
Canaccord Genuity 41st Annual Growth
Conference
- Date and Time:
August 11, 2021: 10:00 a.m. ET
- Webcast:
https://wsw.com/webcast/canaccord60/dcth/2427436
- Management will
also host 1x1 investor meetings during the conference.
To learn more about the events or to schedule a one-on-one
meeting with Delcath’s management, please contact your conference
representative or james@haydenir.com.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company
focused on the treatment of primary and metastatic liver cancers.
The company’s proprietary percutaneous hepatic perfusion (PHP)
system is designed to administer high-dose chemotherapy to the
liver while controlling systemic exposure and associated side
effects. In the United States, the PHP system is being developed
under the tradename HEPZATO KIT (melphalan hydrochloride for
injection/hepatic delivery system), or HEPZATO, and is considered a
combination drug and device product regulated by the United States
Food and Drug Administration (FDA).
In Europe, the PHP system is regulated as a Class IIb medical
device and is approved for sale under the trade name CHEMOSAT
Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has
been used at major medical centers to treat a wide range of cancers
of the liver. CHEMOSAT is being marketed under an exclusive
licensing agreement with medac GmbH, a privately held
multi-national pharmaceutical company headquartered in Germany that
specializes in the treatment and diagnosis of oncological,
urological and autoimmune diseases.
Contact:
Delcath Investor Relations
Email: investorrelations@delcath.com
Hayden IR
James
Carbonara(646)-755-7412james@haydenir.com
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Jul 2023 to Jul 2024